Back to top
more

Entrada Therapeutics (TRDA)

(Delayed Data from NSDQ)

$16.78 USD

16.78
186,586

+0.97 (6.14%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $16.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

Here's Why You Should Invest in BioMarin (BMRN) Stock Now

Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.

Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised

Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.

SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues

SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.